ProCE Banner Activity

Randomized Phase II Trial of Ixazomib + Dexamethasone vs Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
In heavily pretreated patients with relapsed/refractory multiple myeloma, PFS was comparable with ixazomib + dexamethasone and pomalidomide + dexamethasone as shown in a randomized phase II trial.

Released: June 09, 2021

Expiration: June 08, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme